检索结果-南通市图书馆

World Journal of Gastrointestinal Oncology 2024年第6期16卷 2335-2349页

作者： Yu-Jie Shu Bo Lao Ying-Yang Qiu Department of Gastroenterology Yinzhou District Second HospitalNingbo 315199Zhejiang ProvinceChina Yong Loo Lin School of Medicine National University of SingaporeSingapore 119077Singapore

As a highly aggressive tumor,the pathophysiological mechanism of primary liver cancer has attracted much *** recent years,factors such as ferroptosis regulation,lipid peroxidation and metabolic abnormalities have emerged in the study of liver cancer,providing a new perspective for understanding the development of liver *** regulation,lipid peroxidation and metabolic abnormalities play important roles in the occurrence and development of liver *** regulation of ferroptosis is involved in apoptosis and necrosis,affecting cell survival and *** peroxidation promotes oxidative damage and promotes the invasion of liver cancer *** abnormalities,especially the disorders of glucose and lipid metabolism,directly affect the proliferation and growth of liver cancer *** of ferroptosis regulation and lipid peroxidation may help to discover new therapeutic targets and improve therapeutic *** understanding of metabolic abnormalities can provide new ideas for the prevention of liver cancer,and reduce the risk of disease by adjusting the metabolic *** review focuses on the key roles of ferroptosis regulation,lipid peroxidation and metabolic abnormalities in this process.

关键词： Ferroptosis Lipid peroxidation primary liver cancer Lipid metabolism Review

Clinical efficacy of Gamma Knife®combined with transarterial chemoembolization and immunotherapy in the treatment of primary liver cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Surgery 2024年第6期16卷 1601-1608页

作者： Guo-Feng Wang Chang-Xin Shu Xiao-Dong Cai Hong-Bo Wang Jian-Hong Xu Yu-Qing Jia Department of General Surgery Yangzhou Friendship Hospital Affiliated to Medical College of Yangzhou UniversityYangzhou 225000Jiangsu ProvinceChina

BACKGROUND This study was designed to investigate the clinical efficacy and safety of Gamma Knife®combined with transarterial chemoembolization(TACE)and immunotherapy in the treatment of primary liver *** To investigate the clinical efficacy and safety of Gamma Knife®combined with TACE and immune-targeted therapy in the treatment of primary liver *** Clinical data from 51 patients with primary liver cancer admitted to our hospital between May 2018 and October 2022 were retrospectively *** patients underwent Gamma Knife®treatment combined with TACE and *** clinical efficacy,changes in liver function,overall survival(OS),and progression-free survival(PFS)of patients with different treatment responses were evaluated,and adverse reactions were *** The last follow-up for this study was conducted on October 31,*** evaluation of the 51 patients with primary liver cancer revealed a partial response(PR)in 27 patients,accounting for 52.94%(27/51);stable disease(SD)in 16 patients,accounting for 31.37%(16/51);and progressive disease(PD)in 8 patients,accounting for 15.69%(8/51).The objective response rate was 52.94%,and the disease control rate was 84.31%.Alanine aminotransferase,aspartate aminotransferase,lactate dehydrogenase,and alpha-fetoprotein isoform levels decreased after treatment compared with pretreatment(all P=0.000).The median OS was 26 months[95%confidence interval(95%CI):19.946-32.054]in the PR group and 19 months(95%CI:14.156-23.125)in the SD+PD group,with a statistically significant difference(P=0.015).The median PFS was 20 months(95%CI:18.441-34.559)in the PR group and 12 months(95%CI:8.745-13.425)in the SD+PD group,with a statistically significant difference(P=0.002).Common adverse reactions during treatment included nausea and vomiting(39.22%),thrombocytopenia(27.45%),and leukopenia(25.49%),with no treatment-related deaths *** Gamma Knife®combined with TACE and immune-targeted th

关键词： Gamma Knife® Transarterial chemoembolization Immunotherapy primary liver cancer liver function

Effect of CT-Guided Microwave Ablation Combined with TACE on liver Function and Survival of Patients with primary liver cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Nursing Research 2024年第1期8卷 119-124页

作者： Bo Chen Donghong Shi Min Ai Longjiang Zhang Department of Medical Imaging Eastern Theater Command General HospitalNanjing 210002Jiangsu ProvinceChina

Objective:To explore the effect of transarterial chemoembolization(TACE)+CT-guided microwave ablation(MWA)on treating patients with primary liver ***:78 primary liver cancer cases were enrolled and divided into groups according to their assigned surgical *** control group was treated with TACE alone,and the observation group was treated with TACE+CT-guided *** efficacy of the treatment and the liver function indicators and follow-up results of the patients of the two groups were ***:The efficacy of the treatment received by the observation group was higher than that of the control ***,the patients in the observation group exhibited better improvement in liver function indicators after 3 months of ***,the survival rates of 1 and 2 years after surgery of the observation group were all higher than those of the control group(Pprimary liver cancer compared to TACE ***,it resulted in better improvement of liver function and long-term survival ***,this treatment regime should be popularized.

关键词： CT guidance Microwave ablation TACE primary liver cancer liver function Survival status

Data Mining and Systems Pharmacology to Elucidate Effectiveness and Mechanisms of Chinese Medicine in Treating primary liver cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Integrative Medicine 2022年第7期28卷 636-643页

作者： ZHANG Zhen LI Jun-wei ZENG Pu-hua GAO Wen-hui TIAN Xue-fei Department of Internal Medicine College of Integrated Chinese and Western Medicine of Hunan University of Chinese MedicineChangsha 410208China Hunan Key Laboratory of TCM Prescription and Syndromes Translational Medicine Hunan University of Chinese MedicineChangsha 410208China Department of Pharmacy Shenzhen People's Hospital(the Second Clinical Medical CollegeJinan Universitythe First Affiliated HospitalSouthern University of Science and Technology)Shenzhen 518020Guangdong ProvinceChina the First Affiliated Hospital Southern University of Science and Technology)5.Department of OncologyAffiliated Hospital of Hunan Academy of Traditional Chinese MedicineChangsha 410006China

Objective: To identify specific Chinese medicines(CM) that may benefit patients with primary liver cancer(PLC), and to explore the mechanism of action of these medicines. Methods: In this retrospective, singlecenter study, prescription information from PLC patients was used in combination with Traditional Chinese Medicine Inheritance Supports System to identify the specific core drugs. A system pharmacology approach was employed to explore the mechanism of action of these medicines. Results: Taking CM more than 6 months was significantly associated with improved survival outcomes. In total, 77 putative targets and 116 bioactive ingredients of the core drugs were identified and included in the analysis(P<0.05). A total of 1,036 gene ontology terms were found to be enriched in PLC. A total of 75 pathways identified from Kyoto Encyclopedia of Genes and Genomes were also enriched in this disease, including fluid shear stress, interleukin-17 signaling, signaling between advanced glycan end products and their receptors, cellular senescence, tumor necrosis factor signaling, p53 signaling, cell cycle signaling,steroid hormone biosynthesis, T-helper 17 cell differentiation, and metabolism of xenobiotics by cytochrome. Docking studies suggested that the ingredients in the core drugs exert therapeutic effects in PLC by modulating c-Jun and interleukin-6. Conclusions: Receiving CM for 6 months or more improves survival for the patients with PLC. The core drugs that really benefit for PLC patients likely regulates the tumor microenvironment and tumor itself.

关键词： Chinese medicine primary liver cancer system pharmacology bioinformatics tumor microenvironment

Evaluation of high-risk factors and the diagnostic value of alpha-fetoprotein in the stratification of primary liver cancer

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2022年第26期10卷 9264-9275页

作者： Hong-Bin Jiao Wei Wang Meng-Nan Guo Ya-Li Su De-Quan Pang Bao-Lin Wang Jun Shi Jing-Hua Wu Clinical Laboratory Tangshan Maternal and Child Health Care HospitalNorth China University of Science and TechnologyTangshan 063000Hebei ProvinceChina Department of Oncology Tangshan Maternal and Child Health Care HospitalNorth China University of Science and TechnologyTangshan 063000Hebei ProvinceChina Clinical Laboratory Tangshan Nanhu HospitalTangshan 063000Hebei ProvinceChina

BACKGROUND Alpha-fetoprotein(AFP)is one of the diagnostic standards for primary liver cancer(PLC);however,AFP exhibits insufficient sensitivity and specificity for diagnosing *** To evaluate the effects of high-risk factors and the diagnostic value of AFP in stratified *** In total,289 PLC cases from 2013 to 2019 were selected for ***,the contributions of high-risk factors in stratifying PLC were compared according to the following criteria:Child–Pugh score,clinical stage of liver cirrhosis,tumor size,and Barcelona Clinic liver cancer(BCLC)***,the diagnostic value of AFP was evaluated in different stratifications of PLC by receiver operating characteristic *** PLC cases in which AFP played little role,the diagnostic values of carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA 19-9),gamma-glutamyl transferase(GGT),and AFP were *** The roles of high-risk factors differed in stratified *** incidence of smoking and drinking history was higher in PLC with Child–Pugh scores of C(P0.700].However,these measures were meaningless(AUC<0.600)in small hepatomas and BCLC A stage PLC,but could be replaced by the combined detection of CEA,CA 19-9,GGT,and AFP(AUC=0.810 and 0.846,respectively).CONCLUSION Stratification of PLC was essential for precise diagnoses and benefited from evaluating AFP levels.

关键词： primary liver cancer Stratification Risk factors Alpha-fetoprotein Receiver operating characteristic curve Diagnostics

Socioeconomics and attributable etiology of primary liver cancer,1990-2019

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2022年第21期28卷 2361-2382页

作者： Qing-Qing Xing Jing-Mao Li Xuan Dong Dan-Yi Zeng Zhi-Jian Chen Xiao-Yun Lin Jin-Shui Pan Department of Hepatology The First Affiliated Hospital of Fujian Medical UniversityFuzhou 350005Fujian ProvinceChina Hepatology Research Institute Fujian Medical UniversityFuzhou 350005Fujian ProvinceChina Department of Statistics Xiamen UniversityXiamen 361000Fujian ProvinceChina School of Medicine Xiamen UniversityXiamen 361000Fujian ProvinceChina

BACKGROUND primary liver cancer(PLC)is a major contributor to cancer-related *** on global and country-specific levels and trends of PLC are essential for understanding the effects of this disease and helping policymakers to allocate *** To investigate the association between the burden of PLC and socioeconomic development *** cancer mortality and incidence rates were obtained from the Global Burden of Disease(GBD)2019,and the data were stratified by country and territory,sex,and the Socio-demographic Index(SDI)*** association between the attributable etiology of PLC and socioeconomic development status,represented using the SDI,was *** attributable etiology of PLC included hepatitis B,hepatitis C,alcohol use,and nonalcoholic *** association between the attributable etiology of PLC and SDI was further stratified by sex and geographical location.A confidence analysis was also performed based on bootstrap *** The age-standardized incidence rate of PLC was 6.5[95%confidence intervals(CI):5.9-7.2]per 100000 person-years,which decreased by-27.5%(-37.0 to-16.6)from 1990 to *** countries located in East Asia,South Asia,West Africa,and North Africa shouldered the heaviest burden of PLC in *** terms of incidence rates,the first leading underlying cause of PLC identified was hepatitis B,followed by hepatitis C,alcohol use,and nonalcoholic *** stratification using the SDI,the incidence rate of PLC was the highest for high and middle SDI ***,the leading attributable etiologies of PLC were hepatitis B for the middle and high middle SDI locations while hepatitis C and nonalcoholic steatohepatitis for the high SDI *** The pronounced association between socioeconomic development status and PLC burden indicates socioeconomic development status affects attributable etiologies for *** 2019 data are valuable for policymakers implementing PLC cost-e

关键词： Epidemiology Public health Socioeconomics primary liver cancer Hepatitis Alcohol

Efficacy of transcatheter arterial chemoembolization using pirarubicin-loaded microspheres combined with lobaplatin for primary liver cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2022年第27期10卷 9650-9656页

作者： Chao Zhang Yu-Hui Dai Shu-Feng Lian Liang Liu Ting Zhao Jun-Ye Wen Department of Interventional Therapy Hebei North University Affiliated First HospitalZhangjiakou 075000Hebei ProvinceChina Zhangjiakou Qiaoxi District Maternal and Child Health Care Hospital Zhangjiakou 075000Hebei ProvinceChina Department of Hepatobiliary Surgery Hebei People’s HospitalShijiazhuang 050055Hebei ProvinceChina

BACKGROUND Drug-eluting beads show good safety and promising efficacy when used as part of a transarterial chemoembolization regimen for primary liver ***,data on the clinical efficacy and safety of pirarubicin-loaded beads combined with lobaplatin are lacking in *** To evaluate the efficacy and safety of transcatheter arterial chemoembolization using pirarubicin-loaded beads combined with lobaplatin for primary liver *** Between January 2019 and March 2020,60 patients with primary liver cancer were selected at Hebei North University Affiliated First *** to different treatment methods,the participants were categorized into two groups with 30 patients treated with pirarubicin-loaded microspheres combined with lobaplatin included in an observation group and 30 patients treated with pirarubicin emulsion with lipiodol combined with lobaplatin were included in a control *** progression-free survival,overall survival,clinical response rate,disease control rate,liver and kidney function and adverse reactions were compared between the two *** The progression-free survival was 14 mo in the observation group,which was significantly higher than 9 mo of the control group(P0.05).After the treatment,alpha-fetoprotein was 289.06±76.21 ng/m L in the observation group and 365.01±73.11 ng/m L in the control group,which were low in both groups compared wi

关键词： Pirarubicin Drug-loaded microspheres Lobaplatin Transcatheter arterial chemoembolization primary liver cancer

Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

liver Research 2022年第3期6卷 175-180页

作者： Jia-Ren Wang Rui-Ning Li Chao-Yi Huang Chang Hong Qi-Mei Li Lin Zeng Jing-Zhe He Cheng-Yi Hu Hao Cui Li Liu Lu-Shan Xiao Big Data Center Nanfang HospitalSouthern Medical UniversityGuangzhouGuangdongChina Department of Infectious Diseases Nanfang HospitalSouthern Medical UniversityGuangzhouGuangdongChina Department of Infectious Diseases Guangzhou First People's HospitalGuangzhouGuangdongChina

Background and aim:Immune checkpoint inhibitors(ICIs)are widely used in the treatment of liver ***,the interaction with other drugs may change the efficacy of *** studies investigated the effects of antibiotics(ATBs)on the efficacy of immunotherapy and the survival of patients with primary liver cancer receiving *** study aimed to explore the impact of ATBs on the efficacy of immunotherapy in patients with primary liver ***:In total,215 patients with primary liver cancer who received ICIs from June 2018 to October 2020 were included for retrospective *** progression-free survival(PFS),disease control rate(DCR),and overall survival(OS)were compared between patients treated with and without ATBs within 30 days before and after ***:No significant differences in PFS(P=0.376)and OS(P=0.121)were found between patients treated with and without *** and multivariate analyses showed that using ATBs was not associated with PFS,DCR,and ***:The use of ATBs within 30 days before and after immunotherapy in patients with primary liver cancer had no adverse effects on PFS,DCR,and OS.

关键词： Immunotherapy Immune checkpoint inhibitors(ICIs) primary liver cancer Antibiotics(ATBs)

Risk stratification of primary liver cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2022年第26期10卷 9545-9549页

作者： You-Wen Tan Department of Hepatology The Third Hospital of Zhenjiang Affiliated Jiangsu UniversityZhenjiang 212000Jiangsu ProvinceChina

The risk stratification of primary liver cancer(PLC)discussed in a review of viral hepatitis and PLC could lead to misunderstandings by *** example,a single study or a small number of studies cannot comprehensively summarize the risk factors of PLC,is not included in the family history of liver cancer,and chronic hepatitis D is listed as a medium risk factor for the development of ***,PLC prediction models with good clinical validation values have been applied clinically,such as the Toronto hepatocellular carcinoma risk index,REACH-B model,and PAGE-B ***,the Chinese,together with several research societies,have formulated the“Guideline for stratified screening and surveillance of primary liver cancer(2020 edition).”This guideline outlines PLC screening in at-risk populations,both in hospitals and *** is recommended to stratify the at-risk population into four risk levels:low-,intermediate-,high-,and extremely *** is highly recommended and applied in clinical practice.

关键词： Risk factors Model primary liver cancer Hepatocellular carcinoma

Immunotherapy prototype Mark 3.0 model in primary liver cancer:adding locoregional stereotactic therapy and prognostic factors classification management

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Medical Review 2022年第6期2卷 547-552页

作者： Xu Yang Nan Zhang Yang Song Xiaobo Yang Xinting Sang Haitao Zhao Department of liver Surgery State Key Laboratory of Complex Severe and Rare DiseasesPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Department of liver Surgery State Key Laboratory of Complex Severe and Rare DiseasesPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical College(CAMS&PUMC)Beijing 100730China

Immune checkpoint inhibitors(ICIs)like programmed cell death-1(PD-1)/programmed death-ligand 1(PD-L1)inhibitor have shown considerable efficacy in several important cancers including primary liver cancer(PLC)like hepatocellular carcinoma and ***,only some patients with PLC will benefit,so combination therapy and biomarker classification detected by next-generation sequencing or immunohistochemistry are very ***,we briefly summarize ICI-based therapies and stratify these evolving therapies for advanced PLC into three stages of immunotherapies Mark(Mk.)1.0,2.0,and *** illustrated the significance of ICI monotherapy(Mk.1.0),offering combinational approaches with traditional strategies(Mk.2.0)and additional locoregional therapy(Mk.3.0)to achieve longer survival and even meet the“No Evidence of Disease”*** also highlight the importance of biomarkers and prognostic factors for patients with advanced PLC treated with ICI-based ***-plinary team management should be investigated and collaborated closely to manage adverse events and sequential therapy suggestions for patients.

关键词： hepatocellular carcinoma immune checkpoint inhibitors primary liver cancer prognostic factors programmed cell death-1 stereotactic therapy